Free Trial
$100 Off Ends Tonight! MarketBeat All Access Returns to $249
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Save $100 Now
Claim MarketBeat All Access Sale Promotion

MP Advisors Analyst Recommendations & Stock Picks

View the latest stock recommendations issued by analysts at MP Advisors. This page tracks publicly reported analyst upgrades and downgrades, buy/hold/sell ratings, and price target changes for publicly traded companies. All data is compiled from credible public sources and updated regularly to reflect new insights from MP Advisors' equity research team. MarketBeat is not affiliated with or endorsed by MP Advisors.

  • Updated 10/17/2012
Average Return
00.00% 12-Month ROI
Total Ratings
0 Last 12 Months
Buy Ratings
0 Last 12 Months
Sell Ratings
0 Last 12 Months
MarketRank™ evaluates a company based on dividend strength, earnings, valuation, analysts forecasts, and more.
Available with a MarketBeat All Access Subscription
MarketRank™Upgrade to All Access to use the All Ranks Filter
Media sentiment refers to the percentage of positive news stories versus negative news stories a company has received in the past week.
Available with a MarketBeat All Access Subscription
Media SentimentUpgrade to All Access to use the All Sentiments Filter
Analyst consensus is the average investment recommendation among Wall Street research analysts.
Available with a MarketBeat All Access Subscription
Analyst ConsensusUpgrade to All Access to use the All Ratings Filter
CompanyCurrent PriceReport DateAnalystActionPrice TargetRating12-Month Recommendation ROIDetails
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$122.55
+0.1%
10/17/2012 Boost Price Target$45.00 ➝ $50.00OutperformView details for MP Advisors rating of Merck & Co., Inc. (NYSE:MRK) on 10/17/2012
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$122.55
+0.1%
7/13/2012 Upgrade$45.00Market PerformOutperformView details for MP Advisors rating of Merck & Co., Inc. (NYSE:MRK) on 7/13/2012
Amgen Inc. stock logo
AMGN
Amgen
$339.30
5/10/2011 Boost Price Target$63.00 ➝ $65.00OutperformView details for MP Advisors rating of Amgen (NASDAQ:AMGN) on 5/10/2011
Biogen Inc. stock logo
BIIB
Biogen
$193.76
4/15/2011 Upgrade$60.00 ➝ $94.00Market PerformOutperformView details for MP Advisors rating of Biogen (NASDAQ:BIIB) on 4/15/2011
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$638.88
4/7/2011 Upgrade$36.00 ➝ $54.00Market PerformOutperformView details for MP Advisors rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 4/7/2011
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$2.10
2/24/2011 Initiated Coverage$100.00Market PerformView details for MP Advisors rating of Protalix BioTherapeutics (NYSE:PLX) on 2/24/2011
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$638.88
12/16/2010 Downgrade$34.00 ➝ $34.00OutperformMarket PerformView details for MP Advisors rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 12/16/2010
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
$29.01
12/10/2010 DowngradeOutperformMarket PerformView details for MP Advisors rating of Rigel Pharmaceuticals (NASDAQ:RIGL) on 12/10/2010

MarketBeat's community ratings are surveys of what our community members think about MP Advisors and other research firms in the last 90 days. Vote "Outperform" if you believe MP Advisors's recommendations will outperform the broader market over the long term. Vote "Underperform" if you believe MP Advisors's recommendations will underperform the broader market over the long term. You may vote once every thirty days.

Log in to vote on this brokerage.
COMMUNITY RATINGS
2.6out of 5 (last 90 days)
2.6 of 5 stars
OUTPERFORM VOTES
30 Believe will outperform the market
UNDERPERFORM VOTES
27 Believe will underperform the market

Best & Worst Calls